Genetic factors associated with response to as-needed aflibercept therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
Aged
Aged, 80 and over
Alleles
Choroidal Neovascularization
/ drug therapy
Female
Gene Frequency
Genotype
Humans
Macular Degeneration
/ drug therapy
Male
Receptors, Vascular Endothelial Growth Factor
/ administration & dosage
Recombinant Fusion Proteins
/ administration & dosage
Retrospective Studies
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 04 2020
28 04 2020
Historique:
received:
16
01
2020
accepted:
15
04
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
26
11
2020
Statut:
epublish
Résumé
In the present study, we investigated the association between susceptible genetic variants to age-related macular degeneration (AMD) and response to as-needed intravitreal aflibercept injection (IAI) therapy for exudative AMD including both typical neovascular AMD and polypoidal choroidal vasculopathy (PCV) over 12-months. A total of 234 patients with exudative AMD were initially treated with 3 monthly IAI and thereafter as-needed IAI over 12 months. Seven variants of 6 genes including ARMS2 A69S (rs10490924), CFH (I62V:rs800292 and rs1329428), C2-CFB-SKIV2L(rs429608), C3 (rs2241394), CETP (rs3764261) and ADAMTS-9 (rs6795735) were genotyped for all participants using TaqMan technology. After adjusting for age, gender, baseline BCVA and AMD subtype, A (protective) allele of C2-CFB-SKIV2L rs429608 was associated with visual improvement at 12-month (P = 0.003). Retreatment was associated with T(risk) allele of ARMS2 A69S (P = 2.0 × 10
Identifiants
pubmed: 32346038
doi: 10.1038/s41598-020-64301-z
pii: 10.1038/s41598-020-64301-z
pmc: PMC7189239
doi:
Substances chimiques
Recombinant Fusion Proteins
0
aflibercept
15C2VL427D
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7188Subventions
Organisme : MEXT | Japan Society for the Promotion of Science (JSPS)
ID : 19K18841
Pays : International
Références
Kawasaki, R. et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 117, 921–927, https://doi.org/10.1016/j.ophtha.2009.10.007 (2010).
doi: 10.1016/j.ophtha.2009.10.007
pubmed: 20110127
Sakurada, Y. et al. Prevalence and Genetic Characteristics of Geographic Atrophy among Elderly Japanese with Age-Related Macular Degeneration. PLoS One 11, e0149978, https://doi.org/10.1371/journal.pone.0149978 (2016).
doi: 10.1371/journal.pone.0149978
pubmed: 26918864
pmcid: 4769020
Fritsche, L. G. et al. Seven new loci associated with age-related macular degeneration. Nat Genet 45(433-439), 439e431–432, https://doi.org/10.1038/ng.2578 (2013).
doi: 10.1038/ng.2578
Cheng, C. Y. et al. New loci and coding variants confer risk for age-related macular degeneration in East Asians. Nat Commun 6, 6063, https://doi.org/10.1038/ncomms7063 (2015).
doi: 10.1038/ncomms7063
pubmed: 25629512
pmcid: 4317498
Huang, L. et al. A missense variant in FGD6 confers increased risk of polypoidal choroidal vasculopathy. Nat Genet 48, 640–647, https://doi.org/10.1038/ng.3546 (2016).
doi: 10.1038/ng.3546
pubmed: 27089177
Heier, J. S. et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119, 2537–2548, https://doi.org/10.1016/j.ophtha.2012.09.006 (2012).
doi: 10.1016/j.ophtha.2012.09.006
pubmed: 23084240
Lalwani, G. A. et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 148(43-58), e41, https://doi.org/10.1016/j.ajo.2009.01.024 (2009).
doi: 10.1016/j.ajo.2009.01.024
Group, C. R. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364, 1897–1908, https://doi.org/10.1056/NEJMoa1102673 (2011).
doi: 10.1056/NEJMoa1102673
Yamashiro, K. et al. A prospective multicenter study on genome wide associations to ranibizumab treatment outcome for age-related macular degeneration. Sci Rep 7, 9196, https://doi.org/10.1038/s41598-017-09632-0 (2017).
doi: 10.1038/s41598-017-09632-0
pubmed: 28835685
pmcid: 5569099
Sakurada, Y. et al. Association of LOC387715 A69S with vitreous hemorrhage in polypoidal choroidal vasculopathy. Am J Ophthalmol 145, 1058–1062, https://doi.org/10.1016/j.ajo.2008.02.007 (2008).
doi: 10.1016/j.ajo.2008.02.007
pubmed: 18400199
Sakurada, Y. et al. Angiographic lesion size associated with LOC387715 A69S genotype in subfoveal polypoidal choroidal vasculopathy. Retina 29, 1522–1526, https://doi.org/10.1097/IAE.0b013e3181af0d72 (2009).
doi: 10.1097/IAE.0b013e3181af0d72
pubmed: 19898184
Sakurada, Y. et al. Role of complement factor H I62V and age-related maculopathy susceptibility 2 A69S variants in the clinical expression of polypoidal choroidal vasculopathy. Ophthalmology 118, 1402–1407, https://doi.org/10.1016/j.ophtha.2010.12.010 (2011).
doi: 10.1016/j.ophtha.2010.12.010
pubmed: 21397333
Brantley, M. A. Jr. et al. Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration. Am J Ophthalmol 144, 404–408, https://doi.org/10.1016/j.ajo.2007.05.018 (2007).
doi: 10.1016/j.ajo.2007.05.018
pubmed: 17631852
pmcid: 2140051
Hagstrom, S. A. et al. Pharmacogenetics for genes associated with age-related macular degeneration in the Comparison of AMD Treatments Trials (CATT). Ophthalmology 120, 593–599, https://doi.org/10.1016/j.ophtha.2012.11.037 (2013).
doi: 10.1016/j.ophtha.2012.11.037
pubmed: 23337555
pmcid: 3633658
Valverde-Megias, A. et al. ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up. Graefes Arch Clin Exp Ophthalmol 255, 2091–2098, https://doi.org/10.1007/s00417-017-3748-0 (2017).
doi: 10.1007/s00417-017-3748-0
pubmed: 28744656
Sugiyama, A. et al. Retreatment of Exudative Age-Related Macular Degeneration after Loading 3-Monthly Intravitreal Ranibizumab. Ophthalmologica 239, 52–59, https://doi.org/10.1159/000480439 (2018).
doi: 10.1159/000480439
pubmed: 29045945
Miki, A. et al. Common variants in the complement factor H gene confer genetic susceptibility to central serous chorioretinopathy. Ophthalmology 121, 1067–1072, https://doi.org/10.1016/j.ophtha.2013.11.020 (2014).
doi: 10.1016/j.ophtha.2013.11.020
pubmed: 24365176
de Jong, E. K. et al. Chronic central serous chorioretinopathy is associated with genetic variants implicated in age-related macular degeneration. Ophthalmology 122, 562–570, https://doi.org/10.1016/j.ophtha.2014.09.026 (2015).
doi: 10.1016/j.ophtha.2014.09.026
pubmed: 25439433
Hosoda, Y. et al. CFH and VIPR2 as susceptibility loci in choroidal thickness and pachychoroid disease central serous chorioretinopathy. Proc Natl Acad Sci USA 115, 6261–6266, https://doi.org/10.1073/pnas.1802212115 (2018).
doi: 10.1073/pnas.1802212115
pubmed: 29844195
Yoneyama, S. et al. Genetic Factors Associated with Choroidal Vascular Hyperpermeability and Subfoveal Choroidal Thickness in Polypoidal Choroidal Vasculopathy. Retina 36, 1535–1541, https://doi.org/10.1097/IAE.0000000000000964 (2016).
doi: 10.1097/IAE.0000000000000964
pubmed: 26745149
Abedi, F. et al. Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration. Ophthalmology 120, 1641–1648, https://doi.org/10.1016/j.ophtha.2013.01.014 (2013).
doi: 10.1016/j.ophtha.2013.01.014
pubmed: 23582991
Yuan, D. et al. Genetic association with response to intravitreal ranibizumab for neovascular age-related macular degeneration in the Han Chinese population. Ophthalmologica 230, 227–232, https://doi.org/10.1159/000355068 (2013).
doi: 10.1159/000355068
pubmed: 24080590
Fukuda, Y. et al. Clinical and genetic characteristics of pachydrusen in patients with exudative age-related macular degeneration. Sci Rep 9, 11906, https://doi.org/10.1038/s41598-019-48494-6 (2019).
doi: 10.1038/s41598-019-48494-6
pubmed: 31417165
pmcid: 31417165
Yoneyama, S. et al. Genetic variants in the SKIV2L gene in exudative age-related macular degeneration in the Japanese population. Ophthalmic Genet 35, 151–155, https://doi.org/10.3109/13816810.2014.921313 (2014).
doi: 10.3109/13816810.2014.921313
pubmed: 24865191